Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Inhibikase Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +7 vs. Q2 2021
- Shares held
- 4.10M
- +303.7K (+8.0%) vs. Q2 2021
- Total value
- $7.78M
- −$2.84M (−26.7%) vs. Q2 2021
- New holders
- 9
- 6 more added
- Sold out
- 2
- 1 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 122 | $0 | 0.00% | +110+916.7% | Added |
| Rockefeller Capital Management L.P. | 1,500 | $2.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,406 | $10.0K | 0.00% | +5,406 | New |
| UBS Group AG | 8,548 | $16.0K | 0.00% | +8,548 | New |
| Envestnet Asset Management Inc | 10,988 | $21.0K | 0.00% | +10,988 | New |
| Northern Trust Corp | 15,714 | $30.0K | 0.00% | +15,714 | New |
| Shay Capital LLC | 20,000 | $38.0K | 0.01% | +20,000 | New |
| Warberg Asset Management LLC | 26,000 | $49.0K | 0.01% | −64,000−71.1% | Reduced |
| Geode Capital Management, LLC | 25,833 | $49.0K | 0.00% | +25,833 | New |
| Goldman Sachs Group Inc | 27,895 | $53.0K | 0.00% | +27,895 | New |
| Bank of New York Mellon Corp | 39,580 | $75.0K | 0.00% | +39,580 | New |
| BlackRock Inc. | 50,741 | $96.0K | 0.00% | +37,170+273.9% | Added |
| Zeke Capital Advisors, LLC | 93,800 | $178.0K | 0.01% | 00.0% | Unchanged |
| Millennium Management LLC | 101,278 | $192.0K | 0.00% | +101,278 | New |
| Antara Capital LP | 303,000 | $576.0K | 0.11% | +53,000+21.2% | Added |
| Murchinson Ltd. | 320,947 | $610.0K | 0.30% | 00.0% | Unchanged |
| Sabby Management, LLC | 425,014 | $808.0K | 0.18% | +3,814+0.9% | Added |
| FMR LLC | 433,300 | $823.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 478,704 | $909.0K | 0.00% | +8,089+1.7% | Added |
| Kepos Capital LP | 700,000 | $1.33M | 0.09% | 00.0% | Unchanged |
| ACT Capital Management, LLC | 1,010,000 | $1.92M | 0.99% | +135,000+15.4% | Added |
| Altium Capital Management LP | 0 | $0 | 0.00% | −109,749−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |